<DOC>
	<DOCNO>NCT03018405</DOCNO>
	<brief_summary>THINK ( THerapeutic Immunotherapy NKR-2 ) multinational ( EU/US ) open-label Phase I study assess safety clinical activity multiple administration autologous NKR-2 cell seven refractory cancer , include five solid tumor ( colorectal , ovarian , bladder , triple-negative breast pancreatic cancer ) two hematological tumor ( acute myeloid leukemia multiple myeloma ) . The trial test three dose level . At dose , patient receive three successive administration , two week apart , NKR-2 cell . The dose escalation part study enroll 24 patient extension phase would enroll 86 additional patient .</brief_summary>
	<brief_title>A Dose Escalation Phase I Study Assess Safety Clinical Activity Multiple Cancer Indications</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>1 . Men woman â‰¥ 18 year old time sign ICF 2 . Patient Colorectal cancer , epithelial ovarian cell fallopian tube carcinoma , urothelial carcinoma , Triple Negative Breast cancer , pancreatic cancer , AML/MDS Multiple Myeloma 3 . Disease must measurable accord correspond guideline 4 . Patient ECOG performance status 0 1 5 . Patient adequate bone marrow reserve , hepatic renal function Detailed disease specific criterion exist discussed contact list . 1 . Patient tumor metastasis central nervous system 2 . Patients receive another cancer therapy within 2 week plan day apheresis 3 . Patients receive plan receive investigational product within 3 week plan day first NKR2 administration 4 . Patients plan receive concurrent growth factor , systemic steroid immunosuppressive therapy cytotoxic agent 5 . Patients receive cell therapy 6 . Patients underwent major surgery within 4 week plan day first treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>